-
Posted by
Two Blokes 6 hours ago -
Filed in
Stock
-
1 view
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo
